Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
May 18, 2023 02:00 ET
|
Cara Therapeutics, Inc.
ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that...
Cara Therapeutics Reports First Quarter 2023 Financial Results
May 15, 2023 16:01 ET
|
Cara Therapeutics, Inc.
– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company’s share of profit of KORSUVA® (difelikefalin) injection – – Acceleration in demand for KORSUVA injection as...
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
May 01, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
March 14, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
March 06, 2023 16:01 ET
|
Cara Therapeutics, Inc.
– 4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Company’s share of profit of KORSUVA® (difelikefalin) injection; FY22 revenue was $41.9 million including...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
February 21, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
February 08, 2023 17:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
January 17, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...